Hu, Lijun published the artcileDesign, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist, HPLC of Formula: 1877-71-0, the publication is European Journal of Medicinal Chemistry (2021), 113106, database is CAplus and MEDLINE.
Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist I was a suitable lead compound in terms of its high potent and low mol. size, while the docking study of compound I suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and mol. modeling studies based on lead compound I. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound II revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound II protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound II is a promising FXR partial agonist suitable for further investigation.
European Journal of Medicinal Chemistry published new progress about 1877-71-0. 1877-71-0 belongs to esters-buliding-blocks, auxiliary class Carboxylic acid,Benzene,Ester, name is 3-(Methoxycarbonyl)benzoic acid, and the molecular formula is C9H8O4, HPLC of Formula: 1877-71-0.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics